MA71568A - Forme saline et forme cristalline de dérivé de thiénopyrimidinone - Google Patents

Forme saline et forme cristalline de dérivé de thiénopyrimidinone

Info

Publication number
MA71568A
MA71568A MA71568A MA71568A MA71568A MA 71568 A MA71568 A MA 71568A MA 71568 A MA71568 A MA 71568A MA 71568 A MA71568 A MA 71568A MA 71568 A MA71568 A MA 71568A
Authority
MA
Morocco
Prior art keywords
thienopyrimidinone
derivative
crystalline form
salt
salt form
Prior art date
Application number
MA71568A
Other languages
English (en)
Inventor
Bin Liu
Boyu HU
Kevin X Chen
Original Assignee
Cms Research & Development Pte. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cms Research & Development Pte. Ltd. filed Critical Cms Research & Development Pte. Ltd.
Publication of MA71568A publication Critical patent/MA71568A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/02Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/27Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/74Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C215/90Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with quaternised amino groups bound to the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
MA71568A 2022-08-16 2023-08-15 Forme saline et forme cristalline de dérivé de thiénopyrimidinone MA71568A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202210984344 2022-08-16
EP23854433.2A EP4559904A4 (fr) 2022-08-16 2023-08-15 Forme saline et forme cristalline de dérivé de thiénopyrimidinone
PCT/CN2023/113085 WO2024037532A1 (fr) 2022-08-16 2023-08-15 Forme saline et forme cristalline de dérivé de thiénopyrimidinone

Publications (1)

Publication Number Publication Date
MA71568A true MA71568A (fr) 2025-05-30

Family

ID=89940743

Family Applications (1)

Application Number Title Priority Date Filing Date
MA71568A MA71568A (fr) 2022-08-16 2023-08-15 Forme saline et forme cristalline de dérivé de thiénopyrimidinone

Country Status (7)

Country Link
EP (1) EP4559904A4 (fr)
JP (1) JP7801535B2 (fr)
KR (1) KR20250048100A (fr)
CN (1) CN119698409A (fr)
AU (1) AU2023325806A1 (fr)
MA (1) MA71568A (fr)
WO (1) WO2024037532A1 (fr)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1939204E (pt) * 2005-10-19 2013-03-14 Kissei Pharmaceutical Derivado heterocíclico fundido, composição medicinal contendo o mesmo, e sua utilização medicinal
TN2016000121A1 (en) * 2013-10-07 2017-10-06 Bayer Pharma AG Cyclic thienouracil-carboxamides and use thereof
AU2017309015B2 (en) * 2016-08-08 2022-09-15 Kissei Pharmaceutical Co., Ltd. Administration and dosage of therapeutic agent for endometriosis
KR20210100623A (ko) * 2018-11-07 2021-08-17 옵스에파 에스에이 에스트로겐-의존성 장애의 치료를 위한 조성물 및 방법
US20220288154A1 (en) * 2019-08-08 2022-09-15 ObsEva S.A. Gnrh antagonists for the treatment of estrogen-dependent disorders
KR20220061120A (ko) * 2019-08-08 2022-05-12 옵스에파 에스에이 에스트로겐-의존성 장애 치료용 조성물 및 방법
JP7806099B2 (ja) 2021-02-23 2026-01-26 シーエムエス・リサーチ・アンド・ディベロップメント・プライベイト・リミテッド 縮合多環式置換5-カルボン酸チエノピリミジンジオン化合物およびその使用

Also Published As

Publication number Publication date
EP4559904A1 (fr) 2025-05-28
AU2023325806A1 (en) 2025-03-06
CN119698409A (zh) 2025-03-25
JP7801535B2 (ja) 2026-01-16
KR20250048100A (ko) 2025-04-07
JP2025526941A (ja) 2025-08-15
WO2024037532A1 (fr) 2024-02-22
EP4559904A4 (fr) 2025-10-15

Similar Documents

Publication Publication Date Title
MA53226A (fr) Sel et formes cristallines d'omecamtiv mecarbil
EP3947361A4 (fr) Sel et forme cristalline d'un inhibiteur de fak
EP3453703A4 (fr) Forme cristalline e d'un sel de tafamidis méthylglucamine, son procédé de préparation et son application
EP3954693A4 (fr) Forme cristalline d'un inhibiteur d'egfr et procédé de préparation associé
MA55614A (fr) Formes cristallines d'inhibiteur de pyridazinone trpc
EP2155200A4 (fr) Nouveau solvate et formes cristallines de dérivés de carbamoyle-cyclohexane
EP4442694A4 (fr) Nouvelle forme cristalline de trisaccharide
EP3807279A4 (fr) Sels pharmaceutiquement acceptables de sépiaptérine
EP3502103A4 (fr) Forme cristalline, type de sel d'un dérivé de 2-hydro-pyrazole substitué et son procédé de préparation
EA201000104A1 (ru) Производные пиримидина, применимые для лечения воспалительных или аллергических патологических состояний
EP2431355A4 (fr) Nouvelle forme cristalline vi de l'agomélatine son procédé de préparation et son application
MA71568A (fr) Forme saline et forme cristalline de dérivé de thiénopyrimidinone
MA43549A (fr) Alpha-amino esters de dérivé d'hydroxypropylthiazolidine carboxamide, sel et forme cristalline polymorphe correspondants
EP3996707A4 (fr) Formes cristallines d'inhibiteurs de la kallicréine plasmatique
EP4017546A4 (fr) Compositions et méthodes associées pour l'ablation de macrophages m2 et de cellules myéloïdes suppressives
PL4013466T3 (pl) Sposób wytwarzania tkanki chrzęstnej szklistej in vitro
EP3466940A4 (fr) Forme cristalline de l'inhibiteur du cotransporteur de sodium-glucose de type 2
IL317275A (en) Collagen compositions and methods of use thereof
EP4255431A4 (fr) Formes solide de l'émétine
EP3955911A4 (fr) Compositions et méthodes pour inhiber la croissance de cellules sanguines cancéreuses
EP4089086A4 (fr) Forme cristalline de dérivé de pyrrolidinyl-urée et son application
EP4108664A4 (fr) Forme cristalline d'inhibiteur de jak et son application
EP3744712A4 (fr) Formes cristallines de mesaconine et procédé de préparation correspondant
EP4277628C0 (fr) Tasquinomod ou sel pharmaceutiquement acceptable de celui-ci destiné à être utilisé dans le traitement du syndrome myélodysplasique
EP3978486A4 (fr) Forme cristalline d'un inhibiteur de c-met/axl